Molecular Partners AG
MOLN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001745114
No open-market purchases or sales by Molecular Partners AG insiders were filed in the last 90 days; 5 institutions reported holding it in 13F filings for Q2 2026, worth $13.8M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Molecular Partners AG changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 15 | 9 | −6 |
| Shares | 1.72M | 1.41M | −309.0K (−18.0%) |
| Value | $35.1M | $27.7M | −$7.45M (−21.2%) |
New holders (2)
Institutions that held Molecular Partners AG at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BVF Inc | 419,008 | $8.27M | 0.32% |
| Sphera Funds Management Ltd. | 80,555 | $1.58M | 0.16% |
Sold out (8)
Institutions that held Molecular Partners AG at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| BlackRock Inc. | 165,038 | $3.38M |
| Hound Partners, LLC | 121,247 | $2.48M |
| Artal Group S.A. | 100,000 | $2.05M |
| Marshall Wace North America L.P. | 96,499 | $1.97M |
| Capstone Investment Advisors, LLC | 28,741 | $589.0K |
| Old Mission Capital LLC | 14,781 | $303.0K |
| Morgan Stanley | 1,201 | $25.0K |
| UBS Group AG | 23 | $0 |